No abstract available.
Female ; Pregnancy ; Pregnancy, Ectopic*

PURPOSE: We compared the reproducibility of 201Tl and 99mTc-sestamibi (MIBI) gated SPECT measurement of myocardial function using the Germano algorithm. MATERIALS AND METHODS: Gated SPECT acquisition was repeated in the same position in 30 patients who received 201Tl and in 26 who received 99mTc-MIBI. The quantification of end-diastolic volume (EDV), end-systolic volume (ESV), and ejection fraction (EF) on 201Tl and 99mTc-MIBI gated SPECT was processed independently using Cedars quantitative gated SPECT software. The reproducibility of the assessment of myocardial function on 201Tl gated SPECT was compared with that of 99mTc-MIBI gated SPECT. RESULTS: Correlation between the two measurements for volumes and EF was excellent by the repeated gated SPECT studies of 201Tl (r=0.928 to 0.986; p<0.05) and 99mTc-MIBI (r=0.979 to 0.997; p<0.05). However, Bland Altman analysis revealed the 95% limits of agreement (2 SD) for volumes and EF were tighter by repeated 99mTc-MIBI gated SPECT (EDV: 14.1 ml, ESV: 9.4 ml and EF: 5.5%) than by repeated 201Tl gated SPECT (EDV: 24.1 ml, ESV: 18.6 ml and EF: 10.3%). The root mean square (RMS) values of the coefficient of variation (CV) for volumes and EFs were smaller by repeated 99mTc-MIBI gated SPECT (EDV: 2.1 ml, ESV: 2.7 ml and EF: 2.3%) than by repeated 201Tl gated SPECT (EDV: 3.2 ml, ESV: 3.5 ml and EF: 5.2%). CONCLUSION: 99mTc-MIBI provides more reproducible volumes and EF than 201Tl on repeated acquisition gated SPECT. 99mTc-MIBI gated SPECT is the preferable method for the clinical monitoring of myocardial function.
Humans ; Perfusion* ; Technetium Tc 99m Sestamibi ; Tomography, Emission-Computed, Single-Photon*

PURPOSE: To determine diagnostic effects of fine needle aspiration cytology (FNA) and frozen section of thyroid follicular neoplasm and its role in the therapeutic approach. METHOD: We performed a retrospective analysis of the data of patients who underwent thyroid surgery at the Gwangju Christian Hospital, between March 2000 and December 2004, and had a report of preoperative fine needle aspiration (FNA) biopsy of thyroid follicular lesions, which comprises cellular lesion, suspicious for follicular neoplasm or follicular carcinoma. RESULTS: Out of 45 patients with preoperative FNA biopsy diagnosis of follicular neoplasm, reveals true follicular carcinoma in 20 (44.4%), a follicular adenoma in 11 (24.5%), a papillary carcinoma in 7 (15.5%), a papillary carcinoma with follicular variant in 4 (8.9%), an adenomatous goiter in 3 (6.7%). Among the 45 patients having an intraoperative frozen sections, only 7 patients (15.5%) were true follicular carcinoma, suspicious for malignant follicular neoplasm in 14 patients (31.1%) and suspicious for benign follicular neoplasm in 8 patients (17.8%). final diagnosis were changed from suspicious for benign follicular neoplasm at intraoperative frozen section to malignant in 3 patients, from suspicious for malignant follicular neoplasm to benign in 1 patient. Three patients underwent a lobectomy and 1 patients a subtotal thyroidectomy followed by a completion thyroidectomy. CONCLUSION: Fine needle aspiration cytology and frozen section results are not good indicators in making the decision of operative extent. the best way to establish a diagnosis and to predict prognosis is to surgically remove the tumor for a proper histopathologic examination.
Adenoma ; Biopsy ; Biopsy, Fine-Needle* ; Carcinoma, Papillary ; Diagnosis ; Frozen Sections* ; Goiter ; Gwangju ; Humans ; Prognosis ; Retrospective Studies ; Thyroid Gland* ; Thyroidectomy

BACKGROUND/AIMS: Histoacryl forms hard substances in an instance after a brief exposure to polar liquid, blood or body temperature. This often causes obstruction of injector and endoscopic channel. Furthermore, splashed Histoacryl during injection can lead to accidental loss of vision. We propose a new convenient method of Histoacryl-lipiodol sequential injection and report the results. METHODS: From May 2001 to August 2004, sequential injector method was performed in treating consecutive thirty gastric varices patients. Histoacryl (S.G. 1.0) 1 mL and lipiodol (S.G. 1.28) 1~1.5 mL are filled in 2.5 mL disposable syringe with 16 gauge needle, which are separated into two compartments by specific gravity difference. The injector attached side of charged syringe is gently placed upward and the piston is pushed after the lesion site puncture. Then, normal saline is promptly infused to wash out and the needle is withdrawn. RESULTS: There were 26 males and 4 females. 4 had active bleeding and 26 had the stigmata of bleeding. Varices types were Lg-c in 10, Lg-cf in 16 and Lg-f in 4 patients and the Child-Pugh classification were A in 17%, B in 53% and C in 30%. The average amount was 1.53 mL. Initial hemostasis rate was 97%, 3 of patients re-bled in 4 weeks and 2 patients later. One patient died after the procedure and a case of procedure related bacteremia has occurred. CONCLUSIONS: Histoacryl-lipiodol sequential injection by specific gravity difference is convenient and safe. Also, it carries less damage to the instruments.
Bacteremia ; Body Temperature ; Christianity ; Classification ; Enbucrilate ; Esophageal and Gastric Varices* ; Ethiodized Oil ; Female ; Hemorrhage* ; Hemostasis ; Humans ; Male ; Needles ; Punctures ; Specific Gravity ; Syringes ; Varicose Veins

The acute tumor lysis syndrome is an acute illness caused by massive cell lysis after chemotherapies. This syndrome is characterized by hyperuricemia, hyperphosphatemia with hypocalcemia and hyperkalemia. Among these electrolyte abnormalities, the most serious complication is the severe hyperphosphatemia (greater than 14mg/dL) that could result in sudden cardiac arrest or respiratory failure. In order to correct the severe hyperphosphatemia, hemodialysis has been used commonly as the renal replacement therapy . However the hemodialysis can make posthemodialysis serum phosphate rebounded unless the patient take this treatment for more than 6 hours. Therefore it is not sufficient to use hemodialysis treatment alone. To solve this problem, hemodialysis has been used with or replaced by the uninterrupted dialysis technique such as CRRT (continuous renal replacement therapy). We report a 33-year-old man with Burkitt lymphoma who showed severe hyperphosphatemia (peak phosphate value was 18.6mg/dL) during the course of chemotherapy. used with 5 day CAVH (continuous arteriovenous hemofiltration) his phosphate level could be maintained without any rebound. Therefore we concluded that CAVH in conjunction with hemodialysis would be a successful way to control severe hyperphosphatemia associated with tumor lysis syndrome.
Adult ; Burkitt Lymphoma ; Death, Sudden, Cardiac ; Dialysis ; Drug Therapy ; Hemofiltration* ; Humans ; Hyperkalemia ; Hyperphosphatemia* ; Hyperuricemia ; Hypocalcemia ; Renal Dialysis* ; Renal Replacement Therapy ; Respiratory Insufficiency ; Tumor Lysis Syndrome*

BACKGROUND: When aortic stenosis is associated with atrial fibrillation, estimation of the aortic valve area(AVA) by continuity equation refuires averaging of 8-12 beats of LVOT-TVI and AV-TVI to calculate mean LVOT-TVI and mean AV-TVI. Since this method labour intensive, we therefore propose a new simplified method. METHODS: We studied 9 patients of aortic stenosis with atrial fibrillation. We recorded LVOT velocity and aortic valve velocity in 4-chamber view and measure the LVOT area in the parasternal long axis view. We measured RR interval(RR) and diastolic filling time(DFT) of preceding beat in ECG recorded simultaneously. AVA(mean)was defined as the aortic valve area calculated from the mean LVOT-TVI and mean AV_TVI of 10 veats by using continuity equation. AVA)RR), AVA(DFT), AVA(rTT) and AVA-rDDFT) were defined as the aortic valve area calculated from the 1 beat of LVOT-TVI and AV_TVI normalized by RR, DDFT, rRR and rDFT respectively. 20 sets of AVA(mean), AVA(RR), AVA(DFT),AVA(rTT) and AVA(DFT) were calculated in each patient and their means and standard deviations are compared. RESULTS: 1) R values of the correlation of RR, DFT, rTT, rDFT is 0.87, 0.87, 0.89 with LVOT-TVI and 0.91, 0.93, 0.94 with AV-TVI. 2) Averages of AVAs are AVA(mean) 0.76+/-0.35cm2, AVA(rRR) 0.75+/-0.04cm2, AVA(RR) 0.76+/-0.11cm2, AVA(DFT) 0.82+/-0.35cm2, AVA(rRR) 0.75+/-0.15cm2, AVA(rDFP) 0.76+/-0.10cm2. 3) Averages of AVAs showed no significant difference. Standard deviation of AVA(mean) was significantly smaller than other new AVAs(p<0.01). THe standard deviation of AVA(rDFT) was significantly smaller than that of AVA(RR), AVA(DFT) and AVA(RR)(p=0.35, p=0.05,p=0.008). CONCLUSION: When aortic stenosis is associated with atrial fibrillation, newly derived AVA(rDFT) could be more easily calculated compared to conventional AVA(mean) and was also a reproducibe and precise estmate of aortic valve area.
Aortic Valve Stenosis* ; Aortic Valve* ; Atrial Fibrillation* ; Axis, Cervical Vertebra ; Electrocardiography ; Humans

BACKGROUND: Recent investiogations have shown that aortic valve area derived by continuity equation as well as Gorlin formula varied with transvalvular volume flow rate. This study was designed to investigate the effect of heart rate on aortic valve area calculated by continuity equation. METHODS: We studied 10 patients of with cath-proven aortic stenosis. Patients underwent echocardiography recording during right atrial pacing with 80, 100 and 120 beats/min. Flow rate and continuity equation valve area were obtained at each heart rate by doppler echocardiography. RESULTS: Transvalvular flow rates were 194+/-30 ml/sec, 208+/-38 ml/sec and 200+/-39 ml/sec with pacing at 80, 100 and 120 beats/min respectively, and there was no significant change in flow rate with heart rate. Aortic valve areas derived by continuity equation were 0.77+/-0.14cm2, 0.81+/-0.14cm2and 0.86+/-0.15cm2with pacing at 80, 100 and 120 beats/min. There was signifcant increase in aortic valve area between heart rate 120 and 100 beat/min(p=0.02), and between heart rate 120 and 80 beas/min([=0.003). there was no significant change in aortic valve area between heart rate 100 and 80 beat/min. CONCLUSION: Although there was no significant change in transvalvular flow rate with heart rate increase, aortic valve area derived by continuity equation significantly increased with increased heart rate. This relation should be considered when interpretion continuity equation valve area in aortic stenosis.
Aortic Valve Stenosis ; Aortic Valve* ; Echocardiography ; Echocardiography, Doppler ; Heart Rate* ; Heart* ; Humans

BACKGROUND: Darbepoetin alfa is a new erythropoietic agent with a three fold longer terminal half-life than recombinant human erythropoietin (r- HuEPO). The aim of this randomized, open-label study is to determine whether darbepoetin alfa is as effective as r-HuEPO for the treatment of anemia in hemodialysis patients when administered at a reduced dosing frequency. METHODS: A total 74 Korean hemodialysis patients receiving r-HuEPO therapy by either the intravenous (IV) or subcutaneous (SC) route were randomized to continue r-HuEPO or to receive an equivalent dose of darbepoetin alfa at a reduced dosing frequency. Patients receiving r-HuEPO once weekly changed to once every other week darbepoetin alfa, and those receiving r-HuEPO two or three times weekly changed to once-weekly darbepoetin alfa. The initial dose of darbepoetin alfa was based on the r-HuEPO dose at the time of entry into the study, using a formula equating the peptide mass of the two molecules (200 IU r-HuEPO=1 microgram darbepoetin alfa). The doses of r-HuEPO and darbepoetin alfa were titrated to maintain hemoglobin concentrations within -1.0 to +1.5 g/dL of patients' baseline values and within a range of 8.0 to 13.0 g/ dL for up to 20 weeks (16-week dose-titration period followed by a 4-week evaluation period). The primary end point was change in hemoglobin level between baseline and the evaluation period. RESULTS: The mean change in hemoglobin from baseline to the evaluation period was similar in the darbepoetin alfa (-0.03+/-0.19 g/dL) and r-HuEPO (0.27+/-0.20 g/dL) groups, and the difference between the two treatments was -0.30 g/dL (95% CI, -0.84 to 0.23). This was not a statistically significant or clinically relevant difference, despite the reduced frequency of darbepoetin alfa administration. The safety profiles of darbepoetin alfa and r-HuEPO were similar. CONCLUSION: This study suggests that darbepoetin alfa maintains hemoglobin as effectively as r- HuEPO, but with reduced dose frequency.
Anemia* ; Erythropoietin ; Half-Life ; Hemoglobin A ; Humans ; Renal Dialysis* ; Darbepoetin alfa